Completed PHASE3 INTERVENTIONAL 1-arm NCT00425620

Amphotericin B Suspension in Refractory Chronic Sinusitis

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of Intranasal Amphotericin B Suspension in Patients With Refractory, Postsurgical Chronic Sinusitis (CS)

Sponsor: Accentia Biopharmaceuticals

Conditions Chronic Sinusitis

Interventions SinuNase

Updated 7 times since 2017 Last updated: Nov 29, 2007 Started: Dec 31, 2006 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Chronic Sinusitis, this trial is completed. The trial is conducted by Accentia Biopharmaceuticals and has accumulated 7 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Accentia Biopharmaceuticals

Data source: Accentia Biopharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Asheville, United States , Bakersfield, United States , Bangor, United States , Birmingham, United States , Bismarck, United States , Boston, United States , Bozeman, United States , Bridgeport, United States , Buffalo, United States , Centennial, United States and 52 more locations